The Product Liability Handbook

1991 ◽  
Vol 1 (3) ◽  
pp. 99
Author(s):  
Denis Johnston
Keyword(s):  
Author(s):  
Jessica Flanigan

Though rights of self-medication needn’t change medical decision-making for most patients, rights of self-medication have the potential to transform other aspects of healthcare as it is currently practiced. For example, if public officials respected patient’s authority to make medical decisions without authorization from a regulator or a physician, then they should also respect patient’s authority to choose to use unauthorized medical devices and medical providers. And many of the same reasons in favor of rights of self-medication and against prohibitive regulations are also reasons to support patient’s rights to access information about pharmaceuticals, including pharmaceutical advertisements. Rights of self-medication may also call for revisions to existing standards of product liability and prompt officials to rethink justifications for the public provision of healthcare.


1991 ◽  
Vol 6 (1) ◽  
pp. 87-98 ◽  
Author(s):  
Potter Thomas ◽  
Nelson Theron ◽  
Nelson Susan

1980 ◽  
Vol 13 (8) ◽  
pp. 283-283 ◽  

The British Pressure Gauge Manufacturers Association has always emphasised the need for strict observance of recognised safety requirements when using pressure gauges. Unfortunately, gauges are both available and used that do not meet the rigid safety regulations laid down in British Standard 1780 and this could lead to serious accidents. The provisions of the Health and Safety at Work Act coupled with the strengthened proposals for Product Liability will place a greater statutory responsibility upon the manufacturer and user alike. The Association has therefore prepared the following statement:


2009 ◽  
Vol 2 (4) ◽  
Author(s):  
Farhah Abdullah ◽  
Kamaruzaman Jusoff ◽  
Hasiah Mohamed ◽  
Roszainora Setia

1998 ◽  
Vol 92 (1) ◽  
pp. 41-43
Author(s):  
Andreas F. Lowenfeld

In the April 1997 issue of the Journal, I reported on three cases in which the response to an action brought in the court of one country led not to an answer, but to a countersuit in another country—for an antisuit injunction, a declaration of nonliability or both. One of the cases I discussed arose out of a controversy between an asbestos manufacturer, CSR, and a group of insurance companies, the Cigna Group, that may or may not have been obligated to defend and indemnify the manufacturer in respect of claims in the United States for product liability. The manufacturer brought suit in federal court in New Jersey, raising both contract and antitrust claims. The insurers, as I reported, succeeded in securing an antisuit injunction in the Supreme Court of New South Wales (a court of first instance), and thereafter in defeating a motion by the manufacturer to stay or dismiss, on grounds of forum non conveniens, the insurers’ action seeking a declaration of nonliability. I thought that outcome was wrong: in my view, the Australian court should not have stepped into the controversy, and the insurers should have brought their challenge to the jurisdiction and suitable venue of the New Jersey court in that court.


Sign in / Sign up

Export Citation Format

Share Document